PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsHeparin sodium
Heparin sodium
Calciparine, Defencath, Embolex, Heparin (heparin sodium) is an oligosaccharide pharmaceutical. Heparin sodium was first approved as Calciparine on 1982-01-01. It is used to treat cerebral infarction, coronary thrombosis, myocardial infarction, postoperative complications, and pulmonary embolism amongst others in the USA. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
nervous system diseasesD009422
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Heparin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
defencathNew Drug Application2024-12-23
heparinunapproved drug other2012-08-09
heparin sodiumunapproved drug other2014-12-24
heparin sodiumNew Drug Application2025-07-01
heparin sodium and dextroseNew Drug Application2025-07-01
heparin sodium and sodium chlorideNew Drug Application2019-04-19
heparin sodium in dextroseNew Drug Application2023-07-31
heparin sodium in sodium chlorideNew Drug Application2025-03-26
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myocardial infarctionEFO_0000612D009203I21
pulmonary embolismEFO_0003827D011655I26
postoperative complications—D011183—
thromboembolism—D013923—
cerebral infarction—D002544I63
coronary thrombosisEFO_1000883D003328I21
unstable anginaEFO_1000985D000789I20.0
thrombophlebitis—D013924—
Agency Specific
FDA
EMA
Expiration
Code
HEPARIN SODIUM / TAUROLIDINE, DEFENCATH, CORMEDIX
2033-11-15GAIN
2028-11-15NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Heparin Sodium / Taurolidine, Defencath, Cormedix
117381202042-04-15DS, DP
76961822025-05-16DS, DPU-3774
85413932024-11-02DS, DPU-3774
93390362024-11-02DS, DP
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AB: Heparin group antithrombotic drugs
— B01AB01: Heparin
— B01AB51: Heparin, combinations
— B01AC: Platelet aggregation inhibitors excl. heparin
— B01AC30: Platelet aggregation inhibitor combinations excl. heparin
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05B: Antivaricose therapy drugs
— C05BA: Heparins or heparinoids for topical use
— C05BA03: Heparin
— C05BA53: Heparin, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01X: Other ophthalmologicals in atc
— S01XA: Other ophthalmologicals in atc
— S01XA14: Heparin
HCPCS
Code
Description
J1642
Injection, heparin sodium, (heparin lock flush), per 10 units
J1643
Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units
J1644
Injection, heparin sodium, per 1000 units
Clinical
Clinical Trials
1517 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombosisD013927——824464389204
ThromboembolismD013923——417603470179
Venous thromboembolismD054556EFO_0004286I74414452560143
Venous thrombosisD020246—I82.40314302546115
Covid-19D000086382—U07.162630133596
EmbolismD004617——5423242378
Pulmonary embolismD011655EFO_0003827I264322242274
InfarctionD007238EFO_0009463——416272673
Myocardial infarctionD009203EFO_0000612I21—317262571
SyndromeD013577——61710101554
Show 174 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Septic shockD012772—A48.3132—1420
Cardiovascular diseasesD002318EFO_0000319I98—24—1319
Healthy volunteers/patients———1411—419
Newborn respiratory distress syndromeD012127—P22263—513
Type 1 diabetes mellitusD003922EFO_0001359E10332—311
PainD010146EFO_0003843R52—12—911
Multiple myelomaD009101—C90.0341—310
Plasma cell neoplasmsD054219——341—310
Pathologic constrictionD003251———21—58
Pre-eclampsiaD011225EFO_0000668O14—14—37
Show 97 more
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHeparin sodium
INNheparin sodium
Description
Heparin, also known as unfractionated heparin (UFH), is a medication and naturally occurring glycosaminoglycan. Heparin is a blood anticoagulant that increases the activity of antithrombin. It is used in the treatment of heart attacks and unstable angina. It can be given intravenously or by injection under the skin. Its anticoagulant properties make it useful to prevent blood clotting in blood specimen test tubes and kidney dialysis machines.
Classification
Oligosaccharide
Drug classheparin derivatives and low molecular weight (or depolymerized) heparins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID9005-49-6
RxCUI5224
ChEMBL IDCHEMBL1201657
ChEBI ID—
PubChem CID22833565
DrugBankDB01109
UNII IDZZ45AB24CA (ChemIDplus, GSRS)
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
462
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Q9UC78
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 16,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
36,537 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use